211 related articles for article (PubMed ID: 16334200)
1. [Leucemogenesis of chronic myelogenous leukemia].
Mahon FX
Rev Prat; 2005 Oct; 55(15):1642-6. PubMed ID: 16334200
[TBL] [Abstract][Full Text] [Related]
2. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.
Deininger MW; Vieira S; Mendiola R; Schultheis B; Goldman JM; Melo JV
Cancer Res; 2000 Apr; 60(7):2049-55. PubMed ID: 10766197
[TBL] [Abstract][Full Text] [Related]
3. BCR-ABL in chronic myelogenous leukemia--how does it work?
Goldman JM; Melo JV
Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
[TBL] [Abstract][Full Text] [Related]
4. [New approach in the diagnosis and monitoring of treatment in chronic myelogenous leukemia].
Matolcsy A
Orv Hetil; 2004 Dec; 145(52):2603-9. PubMed ID: 15724695
[TBL] [Abstract][Full Text] [Related]
5. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
6. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer.
Zámečníkova A
Expert Rev Hematol; 2010 Feb; 3(1):45-56. PubMed ID: 21082933
[TBL] [Abstract][Full Text] [Related]
7. BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia.
Salesse S; Verfaillie CM
Oncogene; 2002 Dec; 21(56):8547-59. PubMed ID: 12476301
[No Abstract] [Full Text] [Related]
8. Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
Adrián FJ; Ding Q; Sim T; Velentza A; Sloan C; Liu Y; Zhang G; Hur W; Ding S; Manley P; Mestan J; Fabbro D; Gray NS
Nat Chem Biol; 2006 Feb; 2(2):95-102. PubMed ID: 16415863
[TBL] [Abstract][Full Text] [Related]
9. Abl: the prototype of oncogenic fusion proteins.
Saglio G; Cilloni D
Cell Mol Life Sci; 2004 Dec; 61(23):2897-911. PubMed ID: 15583852
[TBL] [Abstract][Full Text] [Related]
10. [Molecular basis of chronic granulocytic leukemia: from test-tube to patient].
Skórski T
Acta Haematol Pol; 1994; 25(2 Suppl 1):184-91. PubMed ID: 8067203
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of Bcr-abl... breaking new ground again.
Ohren JF; Sebolt-Leopold JS
Nat Chem Biol; 2006 Feb; 2(2):63-4. PubMed ID: 16421581
[No Abstract] [Full Text] [Related]
12. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
13. Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.
Melo JV; Deininger MW
Hematol Oncol Clin North Am; 2004 Jun; 18(3):545-68, vii-viii. PubMed ID: 15271392
[TBL] [Abstract][Full Text] [Related]
14. Chronic myelogenous leukemia progenitors display a genetically unstable personality.
Rodrigues MS; Sattler M
J Natl Cancer Inst; 2007 May; 99(9):662-3. PubMed ID: 17470729
[No Abstract] [Full Text] [Related]
15. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
17. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
[TBL] [Abstract][Full Text] [Related]
18. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
[TBL] [Abstract][Full Text] [Related]
20. Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.
Håkansson P; Nilsson B; Andersson A; Lassen C; Gullberg U; Fioretos T
Genes Chromosomes Cancer; 2008 Apr; 47(4):267-75. PubMed ID: 18181176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
